Bortezomib 3.5 mg Injection bulk supplier for pharma manufacturers

Bortezomib 3.5 mg Injection 3.5 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 3.5 mg/vial

Reference Brands: Velcade (USA/EU)

Bortezomib is a proteasome inhibitor used in the treatment of multiple myeloma and mantle cell lymphoma. It works by blocking proteasomes, the enzyme complexes responsible for breaking down proteins in cells, which leads to cancer cell death. Marketed under the brand name Velcade, it is available as a 3.5 mg/vial powder for injection for intravenous or subcutaneous use. It is an essential drug in modern cancer chemotherapy regimens.

Get Enquiry / Request Bulk Quote

Usually answered within 48 hours | GMP documents shared before you commit

Manufacture or export Bortezomib 3.5 mg Injection? List it or send an offer →

Product Description:

Bortezomib is an important anticancer medicine widely used in the treatment of certain blood-related cancers. It belongs to a class of drugs known as proteasome inhibitors and plays a key role in modern oncology therapy. Bortezomib has been approved for use in the initial treatment of multiple myeloma, often in combination with other medicines such as cyclophosphamide and dexamethasone. It is also used in patients who previously responded to treatment and later experienced a relapse after completing prior therapy.

In addition to multiple myeloma, Bortezomib is approved for the treatment of mantle cell lymphoma in patients who have received at least one prior line of therapy. The medicine works by blocking proteasomes, which are responsible for breaking down proteins inside cells. By inhibiting this process, Bortezomib helps disrupt cancer cell growth and can lead to the death of malignant cells.

Due to its proven clinical effectiveness and established role in cancer treatment protocols, Bortezomib is widely used in oncology centers around the world. It is manufactured by several global pharmaceutical companies and is available in different regulated markets, supporting the treatment of patients with complex hematologic malignancies.

Bortezomib 3.5 mg Injection — third party manufacturing & bulk supply

Bortezomib 3.5 mg Injection 3.5 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Bortezomib 3.5 mg Injection is supplied as Injection — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Bortezomib 3.5 mg Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Bortezomib 3.5 mg Injection →

Usually answered within 48 hours, with matched manufacturers, indicative prices and document status.

Back to Listing

Frequently Asked Questions

Bortezomib is used for the treatment of multiple myeloma and mantle cell lymphoma. It works by inhibiting proteasomes in cancer cells, which leads to the accumulation of proteins inside the cells and ultimately helps slow down or stop the growth of cancer cells.

Bortezomib is a synthetic boronic acid–based compound developed through pharmaceutical research. It belongs to a class of medicines known as proteasome inhibitors that target specific cellular processes involved in cancer cell survival.

Common trade names include Velcade, Bortenat, Bortecad, Borviz, and other regional brands available in global markets.

Bortezomib products are manufactured by companies such as Takeda Pharmaceutical Company and Johnson & Johnson for the original brand Velcade, along with several generic manufacturers in India, Europe, and Latin America.

The generic name is Bortezomib.

Well-known brand names include Velcade (US/EU), Bortenat (India), Bortecad (India), Borviz (India), and several other generic brands available in Europe and Latin American markets.

Bortezomib is manufactured in regulated pharmaceutical facilities in countries such as the United States, India, and several European countries under strict oncology drug manufacturing and quality standards.

Velcade (bortezomib) is sold by Takeda in the United States and by Janssen, part of Johnson & Johnson, in most other countries. Velcade is a trademark of its owner; PharmaTradz is not affiliated with or endorsed by Takeda or Johnson & Johnson.

Yes. Generic bortezomib is sold in the United States, Europe, India and many other markets. Some versions come as a freeze-dried powder like Velcade and some as a ready-to-use solution, so check the form your hospitals and registration expect.